Sun Pharma’s Affordable Ozempic Moment And Four Other Big Bets Running Simultaneously

India’s largest drugmaker is juggling a weight-loss drug race, a potential $10 billion acquisition, a skin cancer breakthrough, a regulatory bruising in China, and somehow also a cricket sponsorship. Here’s what it all adds up to.

There is a version of Sun Pharma’s 2026 that looks like a company firing on all cylinders: new drugs reaching patients, a pipeline advancing in Washington, a bold M&A play in the works. There is another version where the cracks are showing: a manufacturing facility in India drawing heat from two major regulators simultaneously, and a market it is trying to dominate filling up with competitors overnight.

The truth, as it usually is with large pharmaceutical companies, is somewhere in the middle. But what is striking about Sun Pharma’s first quarter of 2026 is just how many big bets are live at the same time. The company is not coasting. It is sprinting in several directions at once, and how these threads resolve over the next twelve months will define the company’s next chapter.

The Affordable Ozempic Moment India Has Been Waiting For

Let’s start with the most culturally loaded story. In March 2026, Sun Pharma launched two semaglutide injections in India under the brand names Noveltreat (for weight management) and Sematrinity (for type 2 diabetes). On paper, this is a product launch. In practice, it is Sun Pharma planting a flag in one of the most anticipated pharmaceutical markets in the country’s recent history.

Semaglutide, the molecule behind Ozempic and Wegovy, lost patent protection in India recently, and the scramble that followed was something to behold: over 15 generic versions hit the market almost simultaneously, crashing prices by 50 to 70% relative to Novo Nordisk’s branded products. Sun Pharma’s weekly therapy costs for Noveltreat start at around Rs 900 and cap at Rs 2,000. Sematrinity runs Rs 750 to Rs 1,300. For context, Wegovy was priced well out of reach for most Indian patients. This is, for all practical purposes, India’s affordable Ozempic moment.

“Our endeavour is to provide a high-quality, affordable therapy to a wider patient community in India.” Kirti Ganorkar, Managing Director, Sun Pharma

The need is real. Nearly one in four Indians between 15 and 49 is overweight or obese, and roughly 101 million people in the country live with diabetes. For years, GLP-1 drugs existed in India mostly as aspirational medicine, acknowledged as effective but priced for the few. Sun Pharma’s launch, along with the wave of generics arriving alongside it, changes that calculus meaningfully.

But the moment the floodgates opened, the Indian regulator stepped in.

When the Regulator Blinks First

The CDSCO, India’s Central Drugs Standard Control Organisation, moved quickly once it became clear that cheap semaglutide was flowing freely through online pharmacies, wellness clinics, and WhatsApp groups. On March 10, it issued an advisory to all manufacturers prohibiting surrogate advertising and any indirect promotion that could push people toward off-label, unsupervised use. It then inspected 49 entities across the supply chain and issued notices to those found violating the rules.

Why it matters: GLP-1 drugs are not candy. Side effects range from nausea and vomiting to pancreatitis, kidney injury, and in rare cases, bowel obstruction. In India, they can legally only be prescribed by endocrinologists, internal medicine specialists, and cardiologists. The regulator’s concern is that cheap availability combined with social media hype could push people toward self-medicating with a drug that requires careful clinical monitoring.

The CDSCO’s crackdown does not specifically target Sun Pharma. It is aimed at the entire ecosystem that has grown up around the GLP-1 boom. But it does create a more complicated commercial environment for everyone operating in it. Sun Pharma, to its credit, has framed its launch around a holistic patient support programme and physician-led pathways. Whether that positioning holds as competition intensifies remains to be seen.

Meanwhile, in the United States

Sun Pharma’s India story is messy and dynamic. Its US story, by contrast, is one of methodical portfolio-building, and it is going rather well.

In January 2026, the company commercially launched UNLOXCYT (cosibelimab-ipdl) for adults with advanced cutaneous squamous cell carcinoma, a serious skin cancer that affects around 40,000 Americans each year and kills nearly 15,000. UNLOXCYT is a PD-L1 checkpoint inhibitor, and Sun Pharma claims it stands apart from rivals by engaging both the adaptive and innate immune systems while preserving PD-L2 signalling. The clinical data supports cautious optimism: 71% of patients achieved disease control, and, unusually for this drug class, no patients developed dangerous lung condition pneumonitis at Grade 3 or 4.

Then in March, the FDA accepted a new application for ILUMYA, Sun Pharma’s psoriasis biologic, to treat psoriatic arthritis. A decision is expected by late October 2026. ILUMYA has been on the market since 2018 and has gradually expanded its approved uses: scalp psoriasis in 2024, nail psoriasis in late 2025, and now potentially joints. It has been used by nearly 140,000 patients worldwide. If the psoriatic arthritis approval comes through, it would meaningfully expand the addressable patient population and give the drug a stronger commercial argument against rival biologics.

Taken together, these moves reflect a Sun Pharma that is serious about its ambition to be more than a generics house. Innovative medicines now account for roughly 20% of company sales, and the US pipeline suggests that number is meant to grow.

The China Problem That Won’t Go Away

Not everything is going smoothly. In late January 2026, China’s NMPA, the National Medical Products Administration, ordered a full halt to the import, sale, and use of Sun Pharma’s rivastigmine capsules, a generic treatment for Alzheimer’s disease. The regulator found contamination control failures, excessive impurities in marketed batches, and a quality management department that was not doing its job.

What makes this more than a routine setback is the context. The same Indian manufacturing facility was issued a warning letter by the US FDA in 2024 for significant cGMP violations. Two regulators, two years running, flagging the same site. That is not a coincidence. It is a pattern, and it raises genuine questions about Sun Pharma’s manufacturing quality controls at that facility.

China is not a small market for ageing-related therapies. With one of the fastest-growing elderly populations in the world, it represents exactly the kind of long-term growth opportunity that pharmaceutical companies are fighting to secure. A suspension like this does not just cost revenue. It costs trust, and trust takes longer to rebuild than a manufacturing protocol.

Cricket, of All Things

In what may be the most unexpected item on this list, Sun Pharma signed a three-year deal in February 2026 to become the principal sponsor of the Royal Challengers Bengaluru for the T20 2026 season. The Sun Pharma logo now sits on the front of RCB’s iconic red and black jersey.

This is the company’s first cricket sponsorship, ever. It is worth pausing on why a pharmaceutical company would do this. Sun Pharma is, at its core, a B2B brand: its customers are doctors and pharmacists, not consumers browsing supermarket shelves. But that is changing. With consumer health products growing as a category and brand recognition increasingly mattering in India’s OTC and wellness space, a presence in cricket, which reaches hundreds of millions of people across every demographic, is a different kind of investment than a medical conference. It is Sun Pharma saying: we want ordinary people to know who we are.

The Deal That Could Change Everything

And then there is Organon.

Reports emerged in January 2026 that Sun Pharma submitted a non-binding offer to acquire Organon, the US women’s health and biosimilars company spun out of Merck in 2021, for approximately $10 billion. If completed, this would be the largest cross-border acquisition ever made by an Indian company.

Organon is a complicated target. It was born carrying $9.5 billion in inherited debt from its spinoff, and that debt pile has not shrunk much since. A $1.2 billion acquisition of Dermavant in 2024 strained its balance sheet further, its CEO stepped down in October last year amid allegations of sales irregularities, and it has been actively selling off assets. Sun Pharma had looked at Organon before and walked away. It came back to the table after Organon’s share price fell sharply, which is classic opportunistic M&A logic.

Perspective: Sun Pharma has said publicly that it prefers “tuck-in” acquisitions, smaller targeted deals that add capabilities without taking on undue risk. Organon at $10 billion is anything but a tuck-in. It would require significant leverage and fundamentally change Sun Pharma’s risk profile. The company has called media coverage of the bid “speculative,” which is standard language but does not deny the conversations are happening.

What would Sun Pharma actually be buying? A footprint in women’s health, covering contraception, fertility, and menopause, plus a biosimilars portfolio and an established presence in emerging markets. These are areas where Sun Pharma sees long-term growth and where scale matters. The acquisition of Checkpoint Therapeutics for $416 million in 2025 was a statement of intent on oncology. Organon would be a statement of intent on everything else.

Whether the deal gets done, and at what price, is genuinely uncertain. But the fact that Sun Pharma is even in the conversation says something about where the company sees itself going.

Sun Pharma has always been a company built on discipline and scale: the ability to manufacture at volume, price competitively, and operate in markets others find difficult. That model still works. But 2026 is the year it is also trying to be something more: an innovative medicines company with global ambitions, a consumer brand with cultural resonance, and an acquirer bold enough to attempt the largest deal in Indian corporate history. Whether it can pull all of that off simultaneously, while also fixing a manufacturing facility that two regulators have now flagged, is the question the rest of this year will answer.

_{Disclaimer: Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.}

_{The content in these posts/articles is for informational and educational purposes only and should not be construed as professional financial advice and nor to be construed as an offer to buy /sell or the solicitation of an offer to buy/sell any security or financial products.Users must make their own investment decisions based on their specific investment objective and financial position and using such independent advisors as they believe necessary.}

_{Windmill Capital Team: Windmill Capital Private Limited is a SEBI registered research analyst (Regn. No. INH200007645) based in Bengaluru at No 51 Le Parc Richmonde, Richmond Road, Shanthala Nagar, Bangalore, Karnataka – 560025 creating Thematic & Quantamental curated stock/ETF portfolios. Data analysis is the heart and soul behind our portfolio construction & with 50+ offerings, we have something for everyone. CIN of the company is U74999KA2020PTC132398. For more information and disclosures, visit our disclosures page here.}